Breaking Down IND-Stage Data for Auristatin-S ADC Utilizing Modified Payload to Enhance Tolerability & Therapeutic Index
- Contextualizing Auristatin-S ADC development given tolerability-led narrow therapeutic index from historical clinical ADCs
- Delving into CDX and PDX data highlighting equivalent efficacy profile with improved tolerability and bystander activity
- Breaking down the opportunity of Auristatin-S ADC to be administered at higher dose and deliver clinical benefit melanoma, head and neck, esophageal and NSCLC